This NDC is on FDA's drug shortage list (posted Jun 6, 2018)
Reported reason: Other
Product Information
KETOROLAC 30 MG/ML VIAL is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $1.0175 per ML under NDC 00641604225. Its NADAC has been published 384 times since May 18, 2016.
FDA first approved this application on Jul 21, 2004. Its Orange Book therapeutic-equivalence code is AP.
Strength
30 mg/mL
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00641604225
Classification
Generic
Dosage Form
INJECTION
Route
INTRAMUSCULAR; INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
KETOROLAC TROMETHAMINEApproval Type
Generic (ANDA)
FDA Application
ANDA075772FDA Approved
7/21/2004
TE Code
AP
On Market Since
7/21/2004
Pharmacological Classes
Price Statistics
The NADAC for KETOROLAC 30 MG/ML VIAL has been published 384 times since May 18, 2016, and over the history we have for it it has declined 53.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.0175 per ML |
|---|---|
| All-time high | $4.1276 (Aug 31, 2016) |
| All-time low | $0.7047 (Mar 18, 2026) |
| 52-week high | $1.0778 |
| 52-week low | $0.7047 |
| Median price | $1.3574 |
| Average price | $1.3752 |
| Largest weekly change | +94.7% (Aug 17, 2016) |
| Weeks tracked | 384 |
| Tracking since | May 18, 2016 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 46% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ketorolac Tromethamine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cyclooxygenase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of KETOROLAC 30 MG/ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for KETOROLAC 30 MG/ML VIAL, manufactured by Hikma Pharmaceuticals USA Inc., is $1.0175 per ML (NDC 00641604225), effective Sep 30, 2026.
How has the price of KETOROLAC 30 MG/ML VIAL changed over time?
Over the history we have for it, the NADAC for KETOROLAC 30 MG/ML VIAL has declined 53.3%. It has been tracked across 384 weekly CMS publications since May 18, 2016.
What are the highest and lowest recorded NADAC prices for KETOROLAC 30 MG/ML VIAL?
Since May 18, 2016, the NADAC for KETOROLAC 30 MG/ML VIAL has ranged from a low of $0.7047 (Mar 18, 2026) to a high of $4.1276 (Aug 31, 2016), with a median of $1.3574 per ML.
Are there cheaper alternatives to KETOROLAC 30 MG/ML VIAL?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, KETOROLAC 60 MG/2 ML VIAL, is $0.5524 per ML — about 46% below KETOROLAC 30 MG/ML VIAL.
Who manufactures KETOROLAC 30 MG/ML VIAL?
KETOROLAC 30 MG/ML VIAL (NDC 00641604225) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.
Is KETOROLAC 30 MG/ML VIAL in shortage?
Yes — NDC 00641604225 is currently listed in FDA's drug shortage database (posted Jun 6, 2018). Reported reason: Other.